Oncology and Hematology News and Journal Articles
Cancer Network presents exclusive coverage from the 2015 European Cancer Congress (ECC), held September 25–29 in Vienna.
Older patients taking the oral TKIs sorafenib and sunitinib for RCC had a significantly increased risk for cardiovascular events, particularly stroke.
A new study at a single center in Japan found no significant differences in the rate of BRCA mutations between ovarian cancer patients with or without family histories of the mutations and recommends that BRCA1/2 testing be required for all ovarian cancer patients
Palliative care should be provided with cancer care early in the course of illness for all patients with advanced disease, according to a new guidance statement from ASCO and the American Academy of Hospice and Palliative Medicine.
A novel regimen of carfilzomib, pomalidomide, and dexamethasone was highly active in a group of heavily pretreated patients with relapsed or refractory multiple myeloma.
The US Food and Drug Administration expanded the approval of the anti-PD-1 immunotherapy agent nivolumab to include advanced non-squamous non-small-cell lung cancer.
In this video, Dr. Paz-Ares discusses a phase III study that showed that nivolumab improved survival and response rates in previously treated patients with metastatic non-squamous non-small-cell lung cancer (NSCLC).
In this video, Steven I. Sherman, MD, discusses the final overall survival analysis of the EXAM study, a randomized, placebo-controlled phase III trial of cabozantinib in medullary thyroid carcinoma patients.
In this video, Dr. El-Khoueiry discusses results from a phase I/II study that suggest the PD-1 inhibitor nivolumab is safe and effective in advanced hepatocellular carcinoma.
In this video, Dr. Tap discusses a randomized phase Ib/II trial that found that adding olaratumab to doxorubicin dramatically improved survival in patients with advanced soft-tissue sarcoma.